Drug

Suzhou Rigerna Therapeutics' RG002C0106 Injection Supplemental Application Accepted by China's CDE – Class 1 Chemical Drug Enters Regulatory Review
Clinical trial filingsRigerna Therapeutics

Suzhou Rigerna Therapeutics’ RG002C0106 Injection Supplemental Application Accepted by China’s CDE – Class 1 Chemical Drug Enters Regulatory Review

Data from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) show that a supplemental application for RG002C0106 Injection, submitted by Suzhou Rigerna Therapeutics Co., Ltd.…

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

InnoCare's TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

InnoCare’s TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma
J&JJohnson & Johnson

J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma

DiabetesHighTide Therapeutics

HighTide Therapeutics’ HTD1801 NDA Accepted by NMPA – First-in-Class AMPK/NLRP3 Dual-Target Drug for Type 2 Diabetes

ADC / XDCAstraZeneca

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency – First Treatment for Rare FOLR1 Genetic Disorder
GlaxoSmithKlineGSK

FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency – First Treatment for Rare FOLR1 Genetic Disorder

Show More